無創產前檢測市場:按檢測類型、應用、最終用戶、地區劃分——規模、份額、展望、機會分析,2022-2030 年
市場調查報告書
商品編碼
1149894

無創產前檢測市場:按檢測類型、應用、最終用戶、地區劃分——規模、份額、展望、機會分析,2022-2030 年

Non-invasive Prenatal Testing Market, by Test Type, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

無創產前檢測 (NIPT) 也稱為無創產前篩查 (NIPS)。 NIPT 是一種用於確定胎兒染色體異常和紊亂的方法,通常由染色體缺陷或額外拷貝(非整倍體)引起。 NIPT 尋找在孕婦血液中循環的小脫氧核糖核酸 (DNA) 片段。這些小片段被稱為游離 DNA,因為它們是自由漂浮的。 NIPT 用於檢測 18 三體、13 三體、唐氏綜合症、X 和 Y 染色體的缺失或額外拷貝。 NIPT 已被證明在 COVID-19 大流行期間有助於避免感染風險。在懷孕期間從母體血液中分離胎兒 DNA 和胎兒細胞的可能性揭示了升級無創產前檢測 (NIPT) 的令人興奮的機會。

市場動態

從付款人那裡獲得檢測報銷有望為全球無創產前檢測市場的參與者提供有利可圖的增長機會。鑑於 NIPT 測試的高成本,供應商可能會專注於為供應商提供的 NIPT 測試獲得保險。此外,對健康教育的關注、對 NIPT 的補貼和遺傳諮詢也有望幫助市場增長。例如,2020年9月,中國復旦大學和英國倫敦大學學院的研究人員發現,與中國鄭州的參與者相比,深圳更多的女性聽過NIPT(87.30% vs. 64.03%),願意接受NIPT (91.80% 對 80.43%),更有可能接受 NIPT 但報告的滿意度較低(83.12% 對 54.54%)。

這項研究的主要特點

  • 本報告對全球無創產前檢測市場進行了深入分析,顯示了以 2021 年為基準年的預測期(2022-2030 年)的市場規模和復合年增長率 (CAGR%)。
  • 它揭示了不同細分市場的潛在收入機會,並為該市場概述了一個有吸引力的投資建議矩陣。
  • 它還提供了有關市場驅動因素、制約因素、機會、新產品發布和批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的重要見解。
  • 根據公司亮點、產品組合、主要亮點、財務業績和戰略等參數,對全球無創產前檢測市場的主要參與者進行了概況分析。
  • 參與這項研究的主要公司包括 F. Hoffmann-La Roche Ltd、BGI Group、Berry Genomics Co., Ltd.、Illumina, Inc.、Eurofin Scientific、Natera, Inc.、Sequenom, Inc.、Axia婦女健康、Eluthia、BillionToOne, Inc.、Quest Diagnostics Incorporation.、Igenomix、Agilent Technologies, Inc.、Laboratory Corporation of America Holdings.、PerkinElmer, Inc.、Thermo Fisher Scientific、Yourgene Health PLC
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 《全球無創產前檢測市場》報告面向該行業的各種利益相關者,包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球無創產前檢測市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 按測試類型劃分的市場概況
    • 市場概況:按應用分類
    • 市場概況:按最終用戶分類
    • 市場概況:按地區
  • 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

  • 市場動態
    • 司機
    • 約束因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 近期趨勢
  • 收購和合作場景
  • 技術進步
  • 監管情景

第 4 章全球無創產前檢測 (NIPT) 市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • 總體影響
  • 對供需的影響
  • COVID-19 對市場的影響

第 5 章全球無創產前檢測 (NIPT) 市場,按檢測類型,2017-2030

  • 面板 1 測試
  • 小組 2 測試
  • 第 3 組測試

第 6 章全球無創產前檢測 (NIPT) 市場:按應用分類,2017-2030

  • 三體性
  • 微缺失綜合徵
  • 性染色體異常
  • 其他

第 7 章全球無創產前檢測 (NIPT) 市場:按最終用戶分類,2017-2030

  • 醫院
  • 診斷實驗室
  • 婦產中心

第 8 章全球無創產前檢測 (NIPT) 市場:按地區劃分,2017-2030

  • 北美
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地區
  • 歐洲
  • 英國
  • 德國
  • 意大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東盟
  • 澳大利亞
  • 韓國
  • 其他亞太地區
  • 中東
  • 海灣合作委員會
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第9章競爭格局

  • F. Hoffmann-La Roche Ltd
  • BGI Group
  • Berry Genomics Co., Ltd.
  • Illumina, Inc.
  • Eurofin Scientific
  • Natera, Inc.
  • Sequenom, Inc.
  • Axia Women's Health
  • Eluthia
  • BillionToOne, Inc.
  • Quest Diagnostics Incorporation
  • Agilent Technologies, Inc.
  • Igenomix
  • Laboratory Corporation of America Holdings
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific
  • Yourgene Health PLC

第 10 章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI579

Noninvasive prenatal testing (NIPT) is also known as noninvasive prenatal screening (NIPS). It is a procedure used to determine the chromosomal abnormalities or disorders of the fetus which generally occur due to missing or an extra copy (aneuploidy) of a chromosome. NIPT examines small deoxyribonucleic acid (DNA) fragments which are circulating in the blood of pregnant woman. These small fragments are freely floating and hence are called cell-free DNA. NIPT is carried out for the detection of trisomy 18, trisomy 13, Down syndrome, and missing or extra copies of X and Y chromosomes. NIPT is found to be useful during the COVID-19 pandemic situation to avoid the risk of infection. The potential to isolate fetal DNA and fetal cells from maternal blood during pregnancy has revealed exciting opportunities for upgraded noninvasive prenatal testing (NIPT).

Market Dynamics

Obtaining reimbursement for tests from payers is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market. Vendors may focus on obtaining insurance coverage for NIPT tests offered by them, considering the high costs of these tests. Moreover, attention towards health education, subsidies for NIPT, and genetic counseling is also expected to aid in growth of the market. For instance, in September 2020, researchers from Fudan University, China, and University College London, U.K., reported that, in China, compared with Zhengzhou participants, a higher proportion of Shenzhen women had heard of NIPT (87.30% vs. 64.03%), were willing to receive NIPT (91.80% vs. 80.43%) and had taken NIPT (83.12% vs. 54.54%), while their satisfaction level was lower.

Key features of the study:

  • This report provides an in-depth analysis of the global non-invasive prenatal testing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global non-invasive prenatal testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include include F. Hoffmann-La Roche Ltd, BGI Group, Berry Genomics Co., Ltd., Illumina, Inc., Eurofin Scientific, Natera, Inc., Sequenom, Inc., Axia Women's Health , Eluthia, BillionToOne, Inc., Quest Diagnostics Incorporation., Igenomix, Agilent Technologies, Inc., Laboratory Corporation of America Holdings., PerkinElmer, Inc., Thermo Fisher Scientific, Yourgene Health PLC
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global non-invasive prenatal testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-invasive prenatal testing market

Detailed Segmentation:

  • Global Non-Invasive Prenatal Testing Market, By Test Type:
    • Panel 1 Test
    • Panel 2 Test
    • Panel 3 Test
  • Global Non-Invasive Prenatal Testing Market, By Application:
    • Trisomy
    • Microdeletion Syndrome
    • Sex Chromosome abnormalities
    • Other
  • Global Non-Invasive Prenatal Testing Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Maternity Centers
  • Global Non-Invasive Prenatal Testing Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
      • By Country
    • North Africa
    • Central Africa
    • South Africa
  • Company Profiles
    • F.Hoffmann-La Roche Ltd
      • Company Overview
      • Product Portfolio
      • Market Presence
      • Financial Overview
      • Key Developments
    • Strategies
    • BGI Group
    • Berry Genomics Co., Ltd.
    • Illumina, Inc.
    • Eurofin Scientific
    • Natera, Inc.
    • Sequenom, Inc.
    • Axia Women's Health
    • Eluthia,
    • BillionToOne, Inc.
    • Quest Diagnostics Incorporation.
    • Igenomix
    • Agilent Technologies, Inc.
    • Laboratory Corporation of America Holdings.
    • PerkinElmer, Inc.
    • Thermo Fisher Scientific
    • Yourgene Health PLC

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Test Type
    • Market Snapshot, By Application
    • Market Snapshot, By End User
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Technology Advancements
  • Regulatory Scenario

4. Global Non-invasive Prenatal Testing (NIPT) Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Impact on Supply and Demand
  • COVID-19 Impact on the market

5. Global Non-invasive Prenatal Testing (NIPT) Market, By Test Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Panel 1 Test
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Panel 2 Test
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Panel 3 Test
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Non-invasive Prenatal Testing (NIPT) Market, By Application, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Trisomy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Microdeletion Syndrome
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Sex Chromosome Abnormalities
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Other
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Non-invasive Prenatal Testing (NIPT) Market, By End User, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Diagnostics Laboratories
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Maternity Centers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Non-invasive Prenatal Testing (NIPT) Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • BGI Group
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Berry Genomics Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Illumina, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eurofin Scientific
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Natera, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sequenom, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Axia Women's Health
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eluthia
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • BillionToOne, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Quest Diagnostics Incorporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Agilent Technologies, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Igenomix
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Laboratory Corporation of America Holdings
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PerkinElmer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Thermo Fisher Scientific
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Yourgene Health PLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us